NO761101L - - Google Patents

Info

Publication number
NO761101L
NO761101L NO761101A NO761101A NO761101L NO 761101 L NO761101 L NO 761101L NO 761101 A NO761101 A NO 761101A NO 761101 A NO761101 A NO 761101A NO 761101 L NO761101 L NO 761101L
Authority
NO
Norway
Prior art keywords
preparation
preparation according
carrier component
colon
salts
Prior art date
Application number
NO761101A
Other languages
Norwegian (no)
Inventor
C H Appelgren
C B Bogentoft
J A Sjoegren
Original Assignee
Haessle Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haessle Ab filed Critical Haessle Ab
Publication of NO761101L publication Critical patent/NO761101L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Preparat for kolon.Preparation for colon.

Description

Oppfinnelsen vedrører et preparat beregnet forThe invention relates to a preparation intended for

kolon omfattende en komponent av stiv, makromorfologisk struktur, hvilket preparat er beregnet for behandling av kolon irritabile. colon comprising a component of rigid, macromorphological structure, which preparation is intended for the treatment of irritable bowel syndrome.

Hensikten med oppfinnelsen er å tilveiebringe et preparat for kolon for behandling av kolon irritabile, spesielt The purpose of the invention is to provide a preparation for the colon for the treatment of irritable bowel syndrome, in particular

for å behandle eller hindre utviklingen av divertikler i tykktarmen, (dvs. små follikylære rupturer i veggen av tykktarmen. to treat or prevent the development of diverticula in the colon, (ie small follicular ruptures in the wall of the colon.

Divertikler i tykktarmen blir lett irritert, hvor-ved det oppstår diverticulitis, som gir meget smertefulle tilstander som bare i mange tilfeller kan elimineres ved eliminer-ing av den betente del av tykktarmen. Diverticula in the large intestine are easily irritated, whereupon diverticulitis occurs, which causes very painful conditions that can only be eliminated in many cases by eliminating the inflamed part of the large intestine.

Kolon irritabile er en sykdom som er spesiell for den tilfeldige sivilisasjon. En spastisk tilstand med øket motorisk aktivitet i tykktarmen hører til det patologiske bilde. Dette fører til et øket intraluminalt trykk i kolon som fører Irritable colon is a disease that is peculiar to the casual civilization. A spastic condition with increased motor activity in the colon belongs to the pathological picture. This leads to an increased intraluminal pressure in the leading colon

til dannelse av divertikler, såkalte diverticulosis, med mulighet for en etterfølgende infeksjon, såkalt diverticulitis, som nevnt ovenfor. Dannelsen av divertikler er vanlig og er rapportert å opptre til 56% i en befolkning som har en gjennomsnittsalder på 70 år. Symptomene av kolon irritabile varierer, Det mest vanlige er forandringer i avf^ringsstrukturen, idet både obstipasjon og diare kan opptre i kombinasjon med utvidelse og gass-dannelse. Kolon irritabile er den mest vanlige gastroenterolo-giske sykdom. Den er 2 - 5 ganger så vanlig som mavesår blant pasienter pa en indremedisinsk klinikk. to the formation of diverticula, so-called diverticulosis, with the possibility of a subsequent infection, so-called diverticulitis, as mentioned above. The formation of diverticula is common and is reported to occur in 56% of a population whose average age is 70 years. The symptoms of irritable bowel syndrome vary, the most common being changes in the stool structure, as both constipation and diarrhea can occur in combination with distention and gas formation. Irritable bowel syndrome is the most common gastroenterological disease. It is 2 - 5 times as common as stomach ulcers among patients at an internal medicine clinic.

Enskjønt mekanismen av genesen er kompleks og u-kjent til en viss grad er det et vanlig godtatt faktum at den vanligvis mest alminnelige og altså mest viktige faktor for genesen av divertikularsykdommen er næringsmidler som er for fattige i oppfyllende material. Derved blir mengden feces mindre og tiden for å passere gjennom fordøyelseskanalen er lenger, som igjen fører til spastisk tilstand med øket motorisk aktivitet i tykktarmen. Although the mechanism of the genesis is complex and unknown to a certain extent, it is a commonly accepted fact that the usually most common and thus most important factor for the genesis of diverticular disease is food that is too poor in fulfilling material. Thereby, the amount of faeces is reduced and the time to pass through the digestive tract is longer, which in turn leads to a spastic state with increased motor activity in the large intestine.

Behandlingen har tidligere vært å forandre mat-vaner, dvs. å innta næringsmidler som er mere like i oppfyllende material i kombinasjon med terapeutiske stoffer som antidiare-stoffer, spasmolytiske og antikolinergiske stoffer. Behandlings-typen er imidlertid vanskelig å utføre og har vist seg ikke å være effektiv nok. The treatment has previously been to change eating habits, i.e. to consume foods that are more similar in fulfilling material in combination with therapeutic substances such as antidiarrheal substances, spasmolytic and anticholinergic substances. However, this type of treatment is difficult to perform and has not been shown to be effective enough.

I den senere tid har det fremkommet resultater som viser at hvetekli har en positiv effekt på den divertikulære sykdom. Mengden av feces og passeringstiden gjennom fordøyelses-kanalen øker etter en dose på ca. 20 g kli pr, dag. Videre reduseres det intraluminale trykk i kolon. Den positive effekt av kli skyldes sannsynligvis vannbindingsevnen av klifibrene. Denne kapasitet er avhengig av den omgivende pH. Recently, results have emerged showing that wheat bran has a positive effect on diverticular disease. The amount of faeces and the passage time through the digestive tract increase after a dose of approx. 20 g of bran per day. Furthermore, the intraluminal pressure in the colon is reduced. The positive effect of bran is probably due to the water-binding capacity of the bran fibres. This capacity is dependent on the surrounding pH.

Ulempen ved kli er imidlertid vanskeligheter i å administrere den store mengde kli som er nødvendig for å oppnå en effektiv behandling. Dette skyldes det faktum at kli er vanskelig å håndtere og små mengder herav er ikke effektiv nok til å endre den spastiske tilstand som er tilstede i kolon ved kolon irritabile. Mengden av nødvendig kli er også funnet å være irriterende å svelge, avhengig av en følelse av opphopning av maven den den umiddelbare svelging av den administrerte kli-mengde. However, the disadvantage of bran is difficulty in administering the large amount of bran required to achieve an effective treatment. This is due to the fact that bran is difficult to handle and small amounts of it are not effective enough to change the spastic condition present in the colon in irritable bowel syndrome. The amount of bran required is also found to be irritating to swallow, depending on a feeling of engorgement of the stomach on the immediate swallowing of the administered amount of bran.

Pasienten finner samme problemer også i å benytte andre typer av oppfyllingsdannende stoffer som sterhulia gummi, psyllium-frø og cellulosederivater. The patient also finds the same problems in using other types of fillers such as sterhulia gum, psyllium seeds and cellulose derivatives.

Det idielle middel for å behandle divertikulær-sykdom skulle således være et stoff som ikke absorberes eller nedbrytes i fordøyelseskanalen og som absorberer vann og sveller til et vesentlig større volum i tarmen, spesielt i tykktarmen enn i maven. Videre bør et slikt stoff være i en form så det lett administreres uten å føre til ubehag. The ideal agent for treating diverticular disease should thus be a substance which is not absorbed or broken down in the digestive tract and which absorbs water and swells to a significantly larger volume in the intestine, especially in the large intestine than in the stomach. Furthermore, such a substance should be in a form so that it is easily administered without causing discomfort.

Prepar-atet ifølge oppfinnelsen oppfyller overraskende disse krav og preparatet erkarakterisert vedat stoffet ved siden av nevnte komponent omfatter en forbindelse som har en vannabsorberingsevne under svelling ved pH over 4, idet svellemidlet er valgt blant karboksylpolymere. Ifølge en foretrukken utførelse av oppfinnelsen er midletkarakterisert vedat svelle-forbindelsen sveller ved pH over 5. The preparation according to the invention surprisingly fulfills these requirements and the preparation is characterized in that the substance next to said component comprises a compound which has a water absorption capacity during swelling at a pH above 4, the swelling agent being chosen from among carboxyl polymers. According to a preferred embodiment of the invention, the agent is characterized in that the swelling compound swells at a pH above 5.

I henhold til en annen foretrukket utførelsesform av oppfinnelsen er midletkarakterisert vedat bærekomponenten er et fibrøst cellulosematerial. According to another preferred embodiment of the invention, the agent is characterized in that the carrier component is a fibrous cellulose material.

Ifølge et ytterligere trekk ved oppfinnelsen er midletkarakterisert vedat det består av kli .og polyakrylsyre. According to a further feature of the invention, the agent is characterized by the fact that it consists of bran and polyacrylic acid.

Ifølge en ytterligere foretrukket utførelsesformAccording to a further preferred embodiment

av oppfinnelsen er midletkarakterisert vedat det videre omfatter et bindemiddel og et lipofilt stoff. of the invention, the agent is characterized in that it further comprises a binder and a lipophilic substance.

Oppfinnelsen vedrører også en fremgangsmåte for fremstilling av midlet ifølge oppfinnelsen. Midlet ifølge oppfinnelsen omfatter således en bærende vannabsorberende svellende komponent som er inert overfor prosesser i fordøyelses-kanalen og en forbindelse som sveller ubetydelig i mavens sure pH, men øker betraktelig i volum når det når tarmen. Forholdet mellom komponentene kan variere, men ligger fortrinnsvis i om-rådet på 98 : 2 til 20 : 80. Ved å binde disse sammen idet det benyttes et egnet bindemiddel oppnås lett håndterlig og lett administrerbar form. The invention also relates to a method for producing the agent according to the invention. The agent according to the invention thus comprises a carrying water-absorbing swelling component which is inert to processes in the digestive tract and a compound which swells insignificantly in the acidic pH of the stomach, but increases considerably in volume when it reaches the intestine. The ratio between the components can vary, but is preferably in the range of 98:2 to 20:80. By binding these together using a suitable binder, an easily manageable and easily administrable form is achieved.

Den daglige dose, som er effektiv i behandling av divertikular sykdom, er 2 - 10 g, som er betraktelig lavere enn det som er nødvendig ved å benytte vanlige svellemidler. The daily dose, which is effective in the treatment of diverticular disease, is 2 - 10 g, which is considerably lower than that required by using common bulking agents.

Bærekomponenten har en stiv, makromorfologisk struktur og virker ved siden av sin egen vannabsorberende evne, som en bærer for den annen forbindelse. Prinsippielt kan alle forbindelser som tilfredsstiller dette krav benyttes som en bærekomponent. Fortrinnsvis benyttes polysakkarider av typen cellulose og hemicellulose, som kli av forskjellige korntyper, andre typer av cellulose, fibre, mikrokrystallinsk cellulose ("Avicel")>psyllium-frø eller deler herav. The carrier component has a rigid, macromorphological structure and, in addition to its own water-absorbing capacity, acts as a carrier for the other compound. In principle, all compounds that satisfy this requirement can be used as a carrier component. Polysaccharides of the type cellulose and hemicellulose are preferably used, such as bran of various grain types, other types of cellulose, fibres, microcrystalline cellulose ("Avicel") > psyllium seeds or parts thereof.

Den annen komponent av kolon-preparatet er av den type at det lett absorberer vann og sveller til et visst volum. Dette finner sted i en viss grad under sure betingelser (pH 3)5men dets egenskap øker ved økende pH (3 _ 10) i den vandige opp-løsning. Ved pH som er tilstede i tarmkanalen har volumet øket betraktelig (-2 - 20 ganger) sammenlignet til i maven. Disse forbindelser er fortrinnsvis polymere som har fri karboksygrupper, som polyakrylsyre (Garbopol-typen), karboksypolysakkarider, som Karaja gummi (sterculia gummi), gum ghatti (India gummi), gummi arabicum eller salter herav, som polykarbofil, natriumkarboksy- The second component of the colon preparation is of the type that easily absorbs water and swells to a certain volume. This takes place to a certain extent under acidic conditions (pH 3)5, but its property increases with increasing pH (3 - 10) in the aqueous solution. At the pH present in the intestinal tract, the volume has increased considerably (-2 - 20 times) compared to the stomach. These compounds are preferably polymers having free carboxyl groups, such as polyacrylic acid (Garbopol type), carboxypolysaccharides, such as Karaja gum (sterculia gum), gum ghatti (India gum), gum arabic or salts thereof, such as polycarbophil, sodium carboxy-

metylcellulose, kalsiumalginat.methylcellulose, calcium alginate.

Bindemidlet kan være det vanlige stoff som benyttes som granuleringsmidler ved fremstilling av tabletter og granuler, som polyvinylpyrrolidon, polyvinylacetat, etylcellulose og poly-akrylater• The binder can be the usual substance used as granulating agents in the production of tablets and granules, such as polyvinylpyrrolidone, polyvinyl acetate, ethyl cellulose and polyacrylates•

Disse anvendes fortrinnsvis i kombinasjon med et lyofilt stoff som cetanol, voks, fettsyreestere, glycerolestere et c. These are preferably used in combination with a lyophilic substance such as cetanol, wax, fatty acid esters, glycerol esters et c.

Ytterligere lipofile stoffer kan benyttes for be-legg av den faste sammensetning for å muliggjøre administrering av preparatet når det er tilstede i granulær form. Additional lipophilic substances can be used for coating the solid composition to enable administration of the preparation when it is present in granular form.

Granulene som dannes kan administreres som sådanne eller suspendert i en oppløsning som et slim eller suspensjon. De kan også presses til tabletter. The granules formed can be administered as such or suspended in a solution as a slime or suspension. They can also be pressed into tablets.

Oppfinnelsen skal forklares nærmere ved hjelp av noen eksempler. The invention will be explained in more detail with the help of some examples.

En egnet metode for å bestemme vannabsorberings-kapasiteten av preparatene ifølge oppfinnelsen er følgende: 0,5 g av.preparatet bringes i kontakt med 40 ml av mave- eller tarmsaft i 24 timer. Deretter sentrifugeres blandingen ved 4000'omdreininger pr. minutt i 5 minutter og sentrifugatet fjernes. Mengden som blir tilbake tilsvarer vannabsorberings-kapasiteten av preparatet. A suitable method for determining the water absorption capacity of the preparations according to the invention is the following: 0.5 g of the preparation is brought into contact with 40 ml of gastric or intestinal juice for 24 hours. The mixture is then centrifuged at 4,000 rpm. minute for 5 minutes and the centrifuge is removed. The amount that remains corresponds to the water absorption capacity of the preparation.

Eksempel 1.Example 1.

50 g hvetekli og 20 g "Carbopol" 934 blandes og tilsettes 7 g "Vinnapas" B 100 (polyvinylacetat) og 18 g glyce-rylmonostearat oppløst i metylenklorid/isopropanolblanding (9+1)-Granulene tørkes og males gjennom en sikt 2,4 mm. 50 g of wheat bran and 20 g of "Carbopol" 934 are mixed and 7 g of "Vinnapas" B 100 (polyvinyl acetate) and 18 g of glyceryl monostearate dissolved in a methylene chloride/isopropanol mixture (9+1) are added. The granules are dried and ground through a sieve 2.4 etc.

0,5 g absorberer 2,7 g H20 i mavesaft.0.5 g absorbs 2.7 g H20 in gastric juice.

0,5 g absorberer 18 g H20 i tarmsaft.0.5 g absorbs 18 g H20 in intestinal juice.

Eksempel 2.Example 2.

50 g hvetekli blandes med 20 g kalsiumalginat og 13,4 g "Kollidon" K 90 (polyvinylpyrrolidon) oppløst i isopropanol tilsettes. Granulene tørkes og males gjennom en sikt 2,4 mm. 50 g of wheat bran is mixed with 20 g of calcium alginate and 13.4 g of "Kollidon" K 90 (polyvinylpyrrolidone) dissolved in isopropanol is added. The granules are dried and ground through a 2.4 mm sieve.

0,5 g absorberer 2 g H20 i mavesaft.0.5 g absorbs 2 g H20 in gastric juice.

0,5 g absorberer 8 g H20 i tarmsaft.0.5 g absorbs 8 g H20 in intestinal juice.

Eksempel 3-Example 3-

50 g "Avicel" (mikrokrystallinsk cellulose) blandes med 2 g "Carbopol" 934 og tilsettes 4,2 g "Kollidon" K 90 opp- løst i en blanding av metylenklorid og isopropanol (9+1). Granulene tørkes og presses til tabletter på en Diaf eksenter-presse. 50 g of "Avicel" (microcrystalline cellulose) is mixed with 2 g of "Carbopol" 934 and 4.2 g of "Kollidon" K 90 dissolved in a mixture of methylene chloride and isopropanol (9+1) is added. The granules are dried and pressed into tablets on a Diaf eccentric press.

1 tablett (= 0,5 g) absorberer 1,5 g mavesaft.1 tablet (= 0.5 g) absorbs 1.5 g of gastric juice.

1 tablett (= 0,5 g) absorberer 4,5 g tarmsaft. 1 tablet (= 0.5 g) absorbs 4.5 g of intestinal juice.

Preparatene ifølge oppfinnelsen kan også benyttes ved andre abnorme tilstander i tarmen som obstipasjon, idet feces får en mere normal konsistens og normalt volum, hvilket forbedrer tarmens motoriske aktivitet. The preparations according to the invention can also be used for other abnormal conditions in the intestine such as constipation, as faeces acquire a more normal consistency and normal volume, which improves the motor activity of the intestine.

Claims (1)

1. Preparat for behandling av kolon irritabile som øker volumet av innhold av kolon og nedsetter det intraluminale trykk og omfatter en bærekomponent som har en stiv, makromorfologisk struktur, karakterisert ved at preparatet ved siden av denne komponent omfatter en forbindelse som har en vannabsorbsjonskapasitet under svelling ved pH over pH 4, idet forbindelsen er valgt fra gruppen bestående av karboksylpolymere og salter herav.1. A preparation for the treatment of irritable bowel syndrome that increases the volume of the contents of the colon and lowers the intraluminal pressure and comprises a carrier component that has a rigid, macromorphological structure, characterized in that the preparation next to this component comprises a compound that has a water absorption capacity during swelling at pH above pH 4, the compound being selected from the group consisting of carboxyl polymers and salts thereof. 2. Preparat ifølge krav 1, karakterisert ved at svellemidlet sveller ved pH overstigende 5-3« Preparat ifølge krav 1, karakterisert ved at bærekomponenten er et fibrøst cellulosematerial.2. Preparation according to claim 1, characterized in that the swelling agent swells at a pH exceeding 5-3" Preparation according to claim 1, characterized in that the carrier component is a fibrous cellulose material. 4. Preparat ifølge krav 1, karakterisert ved at svellemidlet er valgt fra gruppen bestående av polyakrylsyre, karboksypolysakkarider, gummi ghatti, gummi arabicum eller salter herav som polykarbofil, natrium-karboksymety1-cellulose og kalsiumalginat.4. Preparation according to claim 1, characterized in that the swelling agent is selected from the group consisting of polyacrylic acid, carboxypolysaccharides, gum ghatti, gum arabic or salts thereof such as polycarbophil, sodium carboxymethyl cellulose and calcium alginate. 5- Preparat ifølge krav 3 og 4, karakter!-sert ved at det består av kli og polyakrylsyre.5- Preparation according to claims 3 and 4, characterized in that it consists of bran and polyacrylic acid. 6. Preparat ifølge ett eller flere av foregående krav, karakterisert ved at det videre omfatter et bindemiddel og et lyofilt stoff.6. Preparation according to one or more of the preceding claims, characterized in that it further comprises a binder and a lyophilic substance. 7- Fremgangsmåte for fremstilling av et preparat ifølge krav 1-6, karakterisert ved at en bærekomponent som har en stiv makromorfologisk struktur settes til ett i vann svellende vannabsorberende stoff, som sveller ved pH overstigende pH 4, idet forbindelsen er valgt fra gruppen bestående av karboksylpolymere og salter herav.7- Method for producing a preparation according to claims 1-6, characterized in that a carrier component which has a rigid macromorphological structure is added to a water-swelling water-absorbing substance, which swells at a pH exceeding pH 4, the compound being selected from the group consisting of carboxyl polymers and salts thereof. 8. Fremgangsmåte ifølge krav 7, karakterisert ved at det vannabsorberende middel sveller ved en pH over 5«8. Method according to claim 7, characterized in that the water-absorbing agent swells at a pH above 5" 9- Fremgangsmåte ifølge krav 7, karakterisert ved at bærekomponenten er et fibrøst cellulosematerial.9- Method according to claim 7, characterized in that the carrier component is a fibrous cellulose material. 10. Fremgangsmåte ifølge krav 7, karakterisert ved at svellmidlet valgt fra gruppen bestående av polyakrylsyre, karboksypolysakkarider, gummi gnatti, gummi arabicum eller salter herav som polykarbofil, natrium-karboksy-metylcellulose og kalsiumalginat.10. Method according to claim 7, characterized in that the swelling agent is selected from the group consisting of polyacrylic acid, carboxypolysaccharides, gum gnatti, gum arabic or salts thereof such as polycarbophil, sodium carboxymethyl cellulose and calcium alginate. 11. Fremgangsmåte ifølge krav 9 og 10, karakterisert ved at bærekomponenten i form av kli settes til polyakrylsyren.11. Method according to claims 9 and 10, characterized in that the carrier component in the form of bran is added to the polyacrylic acid. 12. Fremgangsmåte ifølge ett eller flere av de foregående krav, karakterisert ved at i tillegg tilsettes et bindemiddel og et lipofilt middel oppløst i or-ganisk oppløsningsmiddel til de to komponenter for fremstilling av granuler.12. Method according to one or more of the preceding claims, characterized in that a binder and a lipophilic agent dissolved in organic solvent are additionally added to the two components for the production of granules. 13- Fremgangsmåte for å behandle kolon irritabile hvor det administreres et preparat ifølge et av kravene 1-6 i en mengde stor nok til å øke volumet av innholdet av kolon og å nedsette det intraluminale trykk.13- Method for treating irritable colon where a preparation according to one of claims 1-6 is administered in an amount large enough to increase the volume of the contents of the colon and to reduce the intraluminal pressure.
NO761101A 1975-04-09 1976-03-30 NO761101L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7504049A SE7504049L (en) 1975-04-09 1975-04-09 COLON PREPARATION

Publications (1)

Publication Number Publication Date
NO761101L true NO761101L (en) 1976-10-12

Family

ID=20324216

Family Applications (1)

Application Number Title Priority Date Filing Date
NO761101A NO761101L (en) 1975-04-09 1976-03-30

Country Status (12)

Country Link
BE (1) BE840552A (en)
DE (1) DE2614296A1 (en)
DK (1) DK153376A (en)
FI (1) FI56772C (en)
FR (1) FR2306710A1 (en)
GB (1) GB1538123A (en)
IE (1) IE42793B1 (en)
LU (1) LU74732A1 (en)
NL (1) NL7603600A (en)
NO (1) NO761101L (en)
NZ (1) NZ180552A (en)
SE (1) SE7504049L (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52139715A (en) * 1976-05-14 1977-11-21 Nippon Kayaku Co Ltd Coated granules of alkali polyacrylate
FR2471186A1 (en) * 1979-12-10 1981-06-19 Roussel Uclaf NEW COLIC DELITESCENCE TABLETS AND THEIR PREPARATION PROCESS
US4444761A (en) * 1981-05-04 1984-04-24 Syntex (U.S.A.) Inc. Cellulose/carboxymethyl cellulose mixtures useful for controlling fecal output, and methods employing them
US4521401A (en) * 1983-01-03 1985-06-04 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of quinidine
US4461759A (en) * 1983-01-03 1984-07-24 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of veropamil
US4522804A (en) * 1983-01-03 1985-06-11 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of propranolol
DE3776116D1 (en) * 1986-12-30 1992-02-27 American Cyanamid Co COMPOSITION CONTAINING A POLYCARBOPHIL.
GB8817015D0 (en) * 1988-07-16 1988-08-17 Reckitt & Colmann Prod Ltd Method of treatment
FR2636532B1 (en) * 1988-09-20 1993-11-19 Glaxo Group Ltd PHARMACEUTICAL COMPOSITIONS
MC2288A1 (en) * 1990-05-04 1993-07-14 Perio Prod Ltd COLON-BASED DRUG ADMINISTRATION SYSTEM
IL98087A (en) * 1990-05-04 1996-11-14 Perio Prod Ltd Colonic drug delivery system
DE9212938U1 (en) * 1992-09-25 1992-11-26 Boehringer Ingelheim Gmbh, 6507 Ingelheim Calcium polycarbophil preparation for taking high doses of active ingredients
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
EP3609525A4 (en) 2017-04-14 2020-12-30 Gelesis LLC Compositions and methods for treating or preventing gut permeability-related disorders

Also Published As

Publication number Publication date
FI56772B (en) 1979-12-31
SE7504049L (en) 1976-10-10
NZ180552A (en) 1978-07-28
FI56772C (en) 1980-04-10
FR2306710B1 (en) 1979-07-13
IE42793L (en) 1976-10-09
DK153376A (en) 1976-10-10
FR2306710A1 (en) 1976-11-05
IE42793B1 (en) 1980-10-22
GB1538123A (en) 1979-01-10
DE2614296A1 (en) 1976-10-21
LU74732A1 (en) 1977-02-04
BE840552A (en) 1976-10-11
NL7603600A (en) 1976-10-12
FI760948A (en) 1976-10-10

Similar Documents

Publication Publication Date Title
NO761101L (en)
US5840756A (en) Pharmaceutical composition of L-DOPA ester
JPH045647B2 (en)
WO1998022105A1 (en) Tabletted preparation
WO1984000104A1 (en) Sustained release propranolol tablet
CN101416947A (en) Compound alpha-ketoacid chewing tablet and preparation method
WO2022193723A1 (en) Composition, preparation method therefor, and use thereof
CN101461788A (en) Phloroglucine orally disintegrating tablet and preparation method thereof
JPH1129485A (en) Antiobestic medicine
KR20210042042A (en) Phenolamine G-form crystal, production method and composition and use thereof
CN115804802B (en) Application of euphorbia helioscopia volatile oil in medicine for treating bacterial enteritis
CN101491493A (en) Ferulic acid piperazine slow-release medicine preparation
JP2001523704A (en) Sustained release formulation comprising an α-glucosidase inhibitor
CN101590031B (en) preparation method of disodium sulfodehydroabietate (DSDA) and composition
US3211615A (en) Oral antidiabetic composition and method of use
JPS62207212A (en) Antiallergic agent
JP2005524604A (en) Oral preparation containing activated carbon and use thereof
Marks Cellulose esters in the treatment of constipation
CN114748437B (en) Rebamipide gastric floating tablet and preparation method thereof
RU2648467C2 (en) Prophylactic or therapeutic drug for construction
Block Management of constipation with a refined psyllium combined with dextrose
CN101757007A (en) Melbine/acarbose hypoglycemic oral preparation composition and preparation thereof
CN118845795A (en) Application of sonling new acid in preparing medicine for treating constipation type irritable bowel syndrome
FR1042M (en)
CN101502504A (en) Nimesulide enteric-coated formulation composition and method for preparing the same